Unlocking Skin Solutions: Exploring the Efficacy and Applications of Topical Dermatological Medications for Dermatologic Conditions

The U.S. topical dermatological drugs market focuses on treating skin disorders through creams, gels, and patches. These products address conditions such as eczema, psoriasis, acne, and fungal infections. Topical derma drugs are applied directly to the skin, aiding in the recovery and prevention of skin disorders. They fall into anti-fungal, corticosteroids, local anesthetics, anti-virals, antibiotics, anti-acne, anti-itch, and miscellaneous topical agents. These drugs are widely used for skin care and play a vital role in dermatological health, offering targeted solutions for various skin-related issues.

Access Full Report @ https://www.databridgemarketresearch.com/fr/reports/us-topical-derma-drugs-market

Data Bridge Market Research analyses that the U.S. Topical Dermatological Drugs Market value was USD 4.7 billion in 2022 and is expected to reach USD 9.37 billion by 2030, at a CAGR of 9% from 2023 to 2030. Accessible over-the-counter dermatological products empower self-care, fostering market growth, particularly for addressing mild and common skin conditions without needing a prescription, enhancing consumer convenience and choice.

Key Findings of the Study

The increasing elderly population is expected to drive the market's growth rate

The expanding elderly population faces heightened susceptibility to skin ailments due to age-related functional decline. Issues such as heightened UV sensitivity, infection susceptibility, delayed wound healing, and reduced subcutaneous fat accentuate the demand for dermatological medications. The prevalence of skin conditions rises with age, underscoring the crucial role of dermatological interventions in addressing the specific needs and challenges associated with aging in promoting skin health for the elderly.

Report Scope and Market Segmentation

Segment Analysis:

The U.S. topical derma drugs market is segmented on the basis of severity, drug class, formulation, site, application, population type, mode of purchase, end user, and distribution channel.

• On the basis of severity, the U.S. topical derma drugs market is segmented into mild to moderate, and moderate to severe
• On the basis of drug class, the U.S. topical derma drugs market is segmented into anti-fungal, corticosteroids, local anaesthetics, anti-virals, antibiotics, anti-acne agents, anti-itch agents, miscellaneous topical agents, and others
• On the basis of formulation, the U.S. topical derma drugs market is segmented into patches, gel, ointment, cream, foams, and others
• On the basis of site, the U.S. topical derma drugs market is segmented into surface of the skin, epidermis and dermis
• On the basis of application, the U.S. topical derma drugs market is segmented into acne, cold sores, hives, actinic keratosis, carbuncle, rosacea, eczema, psoriasis, lupus, contact dermatitis, vitiligo, warts, ringworm, impetigo and others
• On the basis of population type, the U.S. topical derma drugs market is segmented into children, and adults
• On the basis of mode of purchase, the U.S. topical derma drugs market is segmented into prescription, and over the counter (OTC)
• On the basis of end user, the U.S. topical derma drugs market is segmented into hospitals, specialty clinics, academic and research institutes and others
• On the basis of distribution channel, the U.S. topical derma drugs market is segmented into retail pharmacy and drug store, hospital pharmacy, online pharmacy, and others

Major Players

Data Bridge Market Research recognizes the following companies as the major U.S. topical dermatological drugs market players in U.S. topical dermatological drugs market are Sanofi (France), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Sanofi (France), Amgen Inc. (U.S.), Lilly (U.S.), AstraZeneca (U.K.), AbbVie Inc. (U.S.), Johnson & Johnson Private Limited (U.S.)

Market Developments

• In September 2022, the US FDA granted approval for Sotyktu (deucravacitinib), an oral medication designed for adults contending with moderate-to-severe plaque psoriasis and seeking systemic therapy or phototherapy. This regulatory endorsement acknowledges Sotyktu as a viable treatment option, marking a significant advancement in addressing the therapeutic needs of individuals dealing with this specific form of psoriasis
• In July 2022, the FDA granted approval for roflumilast cream (ZORYVE) 0.3%, a topical phosphodiesterase-4 (PDE4) inhibitor. This approval marks an innovation in dermatological care, designating roflumilast cream as a targeted treatment for plaque psoriasis in patients aged 12 years and above, offering a novel therapeutic option for managing this skin condition
• In January 2022, AbbVie received FDA approval for Rinvoq, expanding its use to treat refractory, moderate-to-severe atopic dermatitis in individuals aged 12 and older. This approval addresses those who haven't responded to or cannot tolerate prior oral or injectable systemic medications. Rinvoq's endorsement offers a valuable alternative for managing challenging cases of atopic dermatitis in this specific age group, contributing to enhanced treatment options within the dermatological pharmaceutical landscape
• In February 2020, Ortho Dermatologics launched dermatology.com's inaugural non-reimbursed drug service and telemedicine network. This innovative platform enables patients to consult healthcare professionals and acquire branded dermatology products online. The initiative is poised to increase the company's market presence, facilitating both expanded access to medical services and the sale of dermatological products, thereby enhancing Ortho Dermatologics' overall product portfolio and market reach

For more detailed information about the U.S. topical dermatological drugs market report, click here – https://www.databridgemarketresearch.com/fr/reports/us-topical-derma-drugs-market